Immunocore Holdings plc Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 648.23K shares, a 245.80% increase year-over-year.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 27.33K shares, a 77.17% decline year-over-year.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 159.27K shares, a 305.89% increase year-over-year.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 157.93K shares, a 1870.69% increase year-over-year.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 624.41K shares, a 84.08% increase from fiscal 2024.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 339.21K shares, a 79.28% decline from fiscal 2023.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 1.64M shares, a 232.67% increase from fiscal 2022.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 492.16K shares, a 541.15% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 648.23K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 992.77K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 27.33K shares 10-Q · filed 2026-05-06 | 532.00K shares derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | 159.27K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | 624.41K shares 10-K · filed 2026-02-25 |
| 2025-09-30 | 157.93K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 504.38K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 187.46K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 354.46K shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 119.75K shares 10-Q · filed 2025-05-07 | 178.52K shares derived: sum of 4 quarters · filed 2025-05-07 |
| 2024-12-31 | 39.24K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | 339.21K shares 10-K · filed 2025-02-26 |
| 2024-09-30 | 8.01K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | |
| 2024-06-30 | 11.52K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | |
| 2024-03-31 | 280.44K shares 10-Q · filed 2024-05-08 | |
| 2023-12-31 | 1.64M shares 10-K · filed 2024-02-28 | |
| 2022-12-31 | 492.16K shares 10-K · filed 2024-02-28 | |
| 2021-12-31 | 76.76K shares 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |